China · Delayed Price · Currency is CNY Newland Pharmaceutical Company Description
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China.
The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid.
It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium.
The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023.
Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge City, China.
| Country | China |
| Founded | 2005 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,042 |
| CEO | Luwei Zhang |
Contact Details
Address: East side of the southern section of Weiwu Road Changge City, 461500 China | |
| Phone | 86 37 4610 5083 |
| Website | newlandpharma.com |
Stock Details
| Ticker Symbol | 301277 |
| Exchange | Shenzhen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000065K2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Luwei Zhang | GM and Director |
| Qingkui Wang | Financial Director and Accounting Supervisor |
| Chao Liu | Deputy GM, Chief Engineer and Director |
| Yanzi Wu | Secretary of the Board of Directors |
| Liying Wang | Deputy General Manager |